• DOI:10.1007/s40263-016-0362-3
Corpus ID: 40411008

New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?

@article{Beard2016NewPA,
  title={New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?},
  author={E. Beard and L. Shahab and D. Cummings and S. Michie and R. West},
  journal={CNS Drugs},
  year={2016},
  volume={30},
  pages={951-983}
}

E. Beard, L. Shahab, +2 authors R. West

Published 2016

Medicine

CNS Drugs

A wide range of support is available to help smokers to quit and to aid attempts at harm reduction, including three first-line smoking cessation medications: nicotine replacement therapy, varenicline and bupropion. [...] Key Method Six ‘ESCUSE’ criteria—relative efficacy, relative safety, relative cost, relative use (overall impact of effective medication use), relative scope (ability to serve new groups of patients) and relative ease of use—are used. Many of these products are in the early stages of clinical…Expand Abstract

View on Springer

discovery.ucl.ac.uk

Save to Library

Create Alert

Cite

Launch Research Feed